A Prospective Study of the Genomic Landscape of Central Nervous System Disease Secondary to Breast Cancer Utilising Cell-free DNA Derived From Cerebrospinal Fluid (CSF)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The PRIMROSE CSF Study aims to study cerebrospinal fluid (CSF) in patients with breast cancer that has spread to the brain (brain metastasis) or the lining surrounding the brain (leptomeningeal disease). Research into breast cancer that has spread to the brain or the lining of the brain is limited due to difficulty in obtaining brain tissue containing cancer cells. Such tissue is typically only available when tumours are removed, which does not occur in all patients. Evidence indicates an increasing number of patients with breast cancer are developing disease that spreads to the brain or the lining of the brain as treatments improve. The PRIMROSE CSF Study aims to improve understanding of breast cancers that spread to the brain or brain lining by collecting and analysing the fluid that circulates around the brain and comparing these samples with other cancer and blood samples. Cancer cells that have spread to the brain or its lining shed genetic material into the surrounding fluid. Collection of this fluid enables purification of genetic material released by breast cancer cells. This approach allows examination of the genetic profile of breast cancer cells affecting the brain or its lining without the need for surgery. Differences between the original cancer and metastatic disease in the brain can then be analysed. This research will support improved understanding of why certain breast cancers spread to the brain and contribute to the development of new treatments for breast cancer that has spread to the brain or the lining of the brain.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobieta lub mężczyzna
- •Wiek powyżej 18 lat
- •Każdy status receptorów hormonalnych i HER2
- •Świeżo zdiagnozowane przerzuty raka piersi do mózgu LUB nawracające przerzuty po leczeniu LUB choroba opon mózgowych
- •Świadoma zgoda na udział w badaniu
✗ Disqualifies
- •Zbyt duże ryzyko wykonania nakłucia lędźwiowego lub pobrania próbki z rezerwuaru
- •Niemożność wykonywania procedur badania lub wyrażenia świadomej zgody
- •Lekarz uważa, że udział nie leży w najlepszym interesie pacjenta
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 99 Years
- Last updated (source)
- March 31, 2026
- Sex
- No restrictions
Locations (1)
Beaumont RCSI Cancer Centre
Dublin, Ireland
Trial contact
Leonie Young, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.